These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23272809)

  • 1. Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.
    García-Vega Y; García-García I; Collazo-Caballero SE; Santely-Pravia EE; Cruz-Ramírez A; Tuero-Iglesias AD; Alfonso-Alvarado C; Cabrera-Placeres M; Castro-Basart N; Duncan-Roberts Y; Carballo-Treto TI; Soto-Matos J; Izquierdo-Toledo Y; Vázquez-Blomquist D; García-Iglesias E; Bello-Rivero I
    BMC Pharmacol Toxicol; 2012 Dec; 13():20. PubMed ID: 23272809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers.
    García-García I; Hernández-González I; Díaz-Machado A; González-Delgado CA; Pérez-Rodríguez S; García-Vega Y; Campos-Mojena R; Tuero-Iglesias ÁD; Valenzuela-Silva CM; Cruz-Ramírez A; Martín-Trujillo A; Santana-Milián H; López-Saura PA; Bello-Rivero I;
    BMC Pharmacol Toxicol; 2016 Dec; 17(1):58. PubMed ID: 27923408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
    García-García I; González-Delgado CA; Valenzuela-Silva CM; Díaz-Machado A; Cruz-Díaz M; Nodarse-Cuní H; Pérez-Pérez O; Bermúdez-Badell CH; Ferrero-Bibilonia J; Páez-Meireles R; Bello-Rivero I; Castro-Odio FR; López-Saura PA;
    BMC Pharmacol; 2010 Nov; 10():15. PubMed ID: 21092287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers.
    Garcia-Garcia I; Gonzalez-Delgado CA; Valenzuela-Silva C; Hernandez-Bernal F; Ferrero-Bibilonia J; Soto-Hernandez R; Cervantes-Llano M; Ducongé J; Correa-Fernandez A; Olivera-Ruano L; Lopez-Saura P
    Drugs R D; 2004; 5(5):271-80. PubMed ID: 15357626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.
    Khakoo S; Glue P; Grellier L; Wells B; Bell A; Dash C; Murray-Lyon I; Lypnyj D; Flannery B; Walters K; Dusheiko GM
    Br J Clin Pharmacol; 1998 Dec; 46(6):563-70. PubMed ID: 9862245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects.
    Zheng L; Li MP; Gou ZP; Wang Y; Xu N; Cai YM; Luo H
    Br J Clin Pharmacol; 2015 Apr; 79(4):650-9. PubMed ID: 25297637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma.
    Furudate S; Fujimura T; Kakizaki A; Hidaka T; Asano M; Aiba S
    J Dermatol Sci; 2016 Sep; 83(3):182-9. PubMed ID: 27342040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
    Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
    Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Trial of High-Dose Pegylated-Interferon-Alfa-2b Combined With Phototherapy in Advanced Stage Mycosis Fungoides.
    Walker CJ; Espinosa ML; Mehta-Shah N; Pro B; Guitart J; Kuzel T
    J Drugs Dermatol; 2021 Mar; 20(3):349-350. PubMed ID: 33683074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma.
    Spaccarelli N; Rook AH
    Dermatol Clin; 2015 Oct; 33(4):731-45. PubMed ID: 26433845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
    Talpaz M; Rakhit A; Rittweger K; O'Brien S; Cortes J; Fettner S; Hooftman L; Kantarjian H
    Clin Cancer Res; 2005 Sep; 11(17):6247-55. PubMed ID: 16144928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Folliculotropic mycosis fungoides].
    Baratli J; Balakirski G; Megahed M
    Hautarzt; 2014 Dec; 65(12):1011-3. PubMed ID: 25355498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intramuscular low dose alpha-2B interferon and etretinate for treatment of mycosis fungoides.
    Altomare GF; Capella GL; Pigatto PD; Finzi AF
    Int J Dermatol; 1993 Feb; 32(2):138-41. PubMed ID: 8440560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial.
    Huang YW; Qin A; Fang J; Wang TF; Tsai CW; Lin KC; Teng CL; Larouche R
    Br J Clin Pharmacol; 2022 May; 88(5):2396-2407. PubMed ID: 34907578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers.
    Costa MB; Picon PD; Sander GB; Cuni HN; Silva CV; Meireles RP; Góes ACMA; Batoreu NM; Maia MLS; Albuquerque EM; Matos DCS; Saura PL
    BMC Pharmacol Toxicol; 2018 Jan; 19(1):1. PubMed ID: 29301580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
    Motzer RJ; Rakhit A; Ginsberg M; Rittweger K; Vuky J; Yu R; Fettner S; Hooftman L
    J Clin Oncol; 2001 Mar; 19(5):1312-9. PubMed ID: 11230473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial.
    De Leede LG; Humphries JE; Bechet AC; Van Hoogdalem EJ; Verrijk R; Spencer DG
    J Interferon Cytokine Res; 2008 Feb; 28(2):113-22. PubMed ID: 18279106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
    Glue P; Fang JW; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S
    Clin Pharmacol Ther; 2000 Nov; 68(5):556-67. PubMed ID: 11103758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transgenic avian-derived recombinant human interferon-alpha2b (AVI-005) in healthy subjects: an open-label, single-dose, controlled study.
    Patel TB; Pequignot E; Parker SH; Leavitt MC; Greenberg HE; Kraft WK
    Int J Clin Pharmacol Ther; 2007 Mar; 45(3):161-8. PubMed ID: 17416111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha-associated development of bullous lesions in mycosis fungoides.
    Pföhler C; Ugurel S; Seiter S; Wagner A; Tilgen W; Reinhold U
    Dermatology; 2000; 200(1):51-3. PubMed ID: 10681616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.